Pure Global
NCT06410703

CAN1012 Combined With PD-1 in Patients With Solid Tumors

A Phase Ib/IIa, Dose Escalation, Open-Label Study of Intratumoral CAN1012 Combined With PD-1 in Patients With Unresectable or Metastatic Advanced Solid Tumors
Canwell Biotech Limited·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
CAN1012
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Canwell Biotech Limited
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 1/2
Start date
May 30, 2024
End date
May 30, 2026
Enrollment
71 participants
Primary outcome

Safety and tolerability

Summary

This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose escalation
 study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable or Metastatic
 Advanced Solid Tumors who have exhausted options for standard of care therapy.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06410703
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06410703 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Canwell Biotech Limited and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 71 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.